Nanomedicine News

RSS

Dicerna’s DCR-MYC Demonstrates Clinical Anti-Tumor Activity Against Advanced Pancreatic Neuroendocrine Tumors

Dicerna Pharmaceuticals, Inc., a leader in the development of RNAi therapeutics, today presented preliminary safety and efficacy data from an ongoing Phase 1 study of DCR-MYC in patients with advanced solid tumors, multiple myeloma, or lymphoma at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.

2 Jun 2015

Advances in Nanotechnology’ Event at Birmingham UK from 9 June

New technologies designed to eliminate cancers and aid surgical procedures are to be explored at an international nanotechnology conference in Birmingham next month.

1 Jun 2015

LD Micro Invitational: Matinas BioPharma to Present on Targeted Therapeutics

Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"), a clinical-stage biopharmaceutical company principally focused on the development of targeted therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the LD Micro Invitational being held June 1-3, 2015, at the Luxe Sunset Boulevard, Los Angeles, CA.

29 May 2015

Malvern's Nanoparticle Tracking Analysis Used in Development of Targeted microRNA Cancer Therapy at Ohio State University

Researchers in the Department of Chemical and Biomolecular Engineering at The Ohio State University (Columbus, Ohio, USA) are using Malvern Panalytical’ NanoSight Nanoparticle Tracking Analysis (NTA) to study extracellular vesicle yields from different cell culture lines.

From Malvern Panalytical 28 May 2015

Drug-Releasing, Multi-Tasking Electronic Stent Could Help Minimize Risks

Every year, an estimated half-million Americans undergo surgery to have a stent prop open a coronary artery narrowed by plaque. But sometimes the mesh tubes get clogged. Scientists report in the journal ACS Nano a new kind of multi-tasking stent that could minimize the risks associated with the procedure. It can sense blood flow and temperature, store and transmit the information for analysis and can be absorbed by the body after it finishes its job.

From American Chemical Society 28 May 2015

Revolutionary Nanotechnology Could Help Prevent Deep Bone Infections

Leading scientists at the University of Sheffield have discovered nanotechnology could hold the key to preventing deep bone infections, after developing a treatment which prevents bacteria and other harmful microorganisms growing.

28 May 2015

Eighteen Studies Utilizing Nanosphere Verigene Multiplex Infectious Disease Tests Presented at CVS, ECCMID, and MAD-ID

Nanosphere, Inc., a company enhancing medicine through targeted molecular diagnostics, today announced that 18 studies performed by various U.S. and international hospitals were recently presented at the annual Clinical Virology Symposium (CVS) in Daytona Beach, Florida, the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, Denmark, and the Making a Difference in Infectious Diseases (MAD-ID) Conference in Orlando, Florida.

28 May 2015

Small, Simple Chip Can Test for Antibiotic Resistance Within One Hour

We live in fear of 'superbugs': infectious bacteria that don't respond to treatment by antibiotics, and can turn a routine hospital stay into a nightmare. A 2015 Health Canada report estimates that superbugs have already cost Canadians $1 billion, and are a "serious and growing issue." Each year two million people in the U.S. contract antibiotic-resistant infections, and at least 23,000 people die as a direct result.

27 May 2015

FDA Grants Orphan Drug Designation to Cerulean’s CRLX101 Nanoparticle-Drug Conjugate

Cerulean Pharma Inc. today announced that the U.S. Food and Drug Administration, or FDA, has granted orphan drug designation to CRLX101 for the treatment of ovarian cancer.

27 May 2015

Matinas BioPharma to Present Amphotericin B Nano-Particle Formulation at SeeThru Equity Microcap Investor Conference

Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"), a clinical-stage biopharmaceutical company principally focused on the development of lipid-based prescription therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the Fourth Annual SeeThru Equity Microcap Investor Conference being held May 28, 2015, at Convene Grand Central, New York, NY.

27 May 2015

Nanomedicine News

Dicerna’s DCR-MYC Demonstrates Clinical Anti-Tumor Activity Against Advanced Pancreatic Neuroendocrine Tumors

Advances in Nanotechnology’ Event at Birmingham UK from 9 June

LD Micro Invitational: Matinas BioPharma to Present on Targeted Therapeutics

Malvern's Nanoparticle Tracking Analysis Used in Development of Targeted microRNA Cancer Therapy at Ohio State University

Drug-Releasing, Multi-Tasking Electronic Stent Could Help Minimize Risks

Revolutionary Nanotechnology Could Help Prevent Deep Bone Infections

Eighteen Studies Utilizing Nanosphere Verigene Multiplex Infectious Disease Tests Presented at CVS, ECCMID, and MAD-ID

Small, Simple Chip Can Test for Antibiotic Resistance Within One Hour

FDA Grants Orphan Drug Designation to Cerulean’s CRLX101 Nanoparticle-Drug Conjugate

Matinas BioPharma to Present Amphotericin B Nano-Particle Formulation at SeeThru Equity Microcap Investor Conference

Combining Nanofluids and Turbulators for Sustainable Energy

Enhancing Material Properties through Nanotube Encapsulation

Brain-Inspired Nano-Tech Promises New Era for Electronics

Breakthrough in 2D Material Growth Opens Doors to Cleaner Energy and Next-Generation Technology

Sustainable ZnO Nanoparticles for Methylene Blue Cleanup

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Conversations on AFM: Applications of BioAFM in Life Science

Sponsored Content

Characterization of Active Pharmaceutical Ingredients, Injectables, and Proteins

The Future of Wound Care: Why Nanofibers are Key to Accelerated Healing

The Evolution of Lipid Nanoparticles

How Emulsion Electrospinning is Transforming Materials